Predictions
Chimerix Inc.
Start price
Target price
Perf. (%)
€1.19
24.06.23
24.06.23
€3.00
31.03.26
31.03.26
-27.97%
18:13
18:13
Could be very worthwhile Investment >20% year
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€38.49
24.06.23
24.06.23
€50.00
31.03.26
31.03.26
-48.39%
18:32
18:32
Could be very worthwhile Investment >20% year
Cymabay Therapeutics Inc
Start price
Target price
Perf. (%)
€6.95
24.06.23
24.06.23
€20.00
31.03.26
31.03.26
101.44%
01.10.23
01.10.23
Could be very worthwhile Investment >20% year
Geron Corp.
Start price
Target price
Perf. (%)
€2.88
24.06.23
24.06.23
€4.00
30.04.26
30.04.26
-27.18%
03.03.24
03.03.24
Could be very worthwhile Investment >20% year
Heron Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.12
24.06.23
24.06.23
€2.30
31.03.26
31.03.26
51.79%
08.01.24
08.01.24
Could be very worthwhile Investment >20% year
Immunogen Inc.
Start price
Target price
Perf. (%)
€18.52
24.06.23
24.06.23
€30.00
31.12.25
31.12.25
-5.02%
30.07.23
30.07.23
Could be very worthwhile Investment >20% year
Immutep LTD ADR
Start price
Target price
Perf. (%)
€1.75
24.06.23
24.06.23
€4.00
31.12.25
31.12.25
25.71%
15:54
15:54
Could be very worthwhile Investment >20% year
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€58.60
24.06.23
24.06.23
€90.00
30.06.26
30.06.26
18.43%
19.02.24
19.02.24
Could be very worthwhile Investment >20% year
Krystal Biotech
Start price
Target price
Perf. (%)
€105.00
24.06.23
24.06.23
€200.00
30.04.26
30.04.26
68.86%
09:55
09:55
Could be very worthwhile Investment >20% year
Madrigal Pharmaceuticals inc.
Start price
Target price
Perf. (%)
€214.90
24.06.23
24.06.23
€380.00
31.05.26
31.05.26
3.30%
12:16
12:16
Could be very worthwhile Investment >20% year
Prothena Corp. plc
Start price
Target price
Perf. (%)
€62.00
24.06.23
24.06.23
€90.00
31.03.26
31.03.26
-68.71%
27.08.24
27.08.24
Could be very worthwhile Investment >20% year
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€44.20
24.06.23
24.06.23
€60.00
31.12.25
31.12.25
-83.14%
19.08.24
19.08.24
Could be very worthwhile Investment >20% year
Syros Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.68
24.06.23
24.06.23
€4.00
31.12.25
31.12.25
36.94%
01.10.23
01.10.23
Could be very worthwhile Investment >20% year
NVIDIA Corp.
Start price
Target price
Perf. (%)
€38.80
24.06.23
24.06.23
€100.00
31.12.27
31.12.27
10.31%
02.12.23
02.12.23
Could be very worthwhile Investment >20% year
NVIDIA Corp.
Start price
Target price
Perf. (%)
€38.80
24.06.23
24.06.23
€100.00
31.12.27
31.12.27
10.31%
02.12.23
02.12.23
Could be very worthwhile Investment >20% year
NVIDIA Corp.
Start price
Target price
Perf. (%)
€38.80
24.06.23
24.06.23
€100.00
31.12.27
31.12.27
10.31%
02.12.23
02.12.23
Could be very worthwhile Investment >20% year
Viking Therapeutics Inc
Start price
Target price
Perf. (%)
€18.54
24.06.23
24.06.23
€27.00
31.12.25
31.12.25
347.68%
03.03.24
03.03.24
Could be very worthwhile Investment >20% year
Voyager Therapeutics Inc
Start price
Target price
Perf. (%)
€10.60
24.06.23
24.06.23
€20.00
31.12.25
31.12.25
-43.30%
22.08.24
22.08.24
Could be very worthwhile Investment >20% year
Protagonist Therapeutics Inc
Start price
Target price
Perf. (%)
€21.80
24.06.23
24.06.23
€40.00
31.12.25
31.12.25
-
31.08.23
31.08.23
Could be very worthwhile Investment >20% year
Apple Inc.
Start price
Target price
Perf. (%)
€171.66
23.06.23
23.06.23
-
23.07.23
23.07.23
-0.30%
26.06.23
26.06.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
Apple Inc.
Start price
Target price
Perf. (%)
€171.66
23.06.23
23.06.23
-
23.07.23
23.07.23
-0.30%
26.06.23
26.06.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected
Apple Inc.
Start price
Target price
Perf. (%)
€171.66
23.06.23
23.06.23
-
23.07.23
23.07.23
-0.30%
26.06.23
26.06.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Very high dividend yield expected
EBIT growth > 30% per year expected